In future, Danish regions will be able to save DKK 100 mill. annually on medicines to treat ER+/HER2- locally advanced or metastatic breast cancer, with no impairment in the treatment.
This is the outcome of a tendering procedure conducted by Amgros, the regions' procurement organisation, and a new medicine recommendation approved by the Danish Medicines Council. The recommendation states the medicines the Danish Medicines Council recommends as first, second and third choice to treat this type of breast cancer.
The recommendation and the tendering procedure come after the Danish Medicines Council ranked three different medicines as equal for treating ER+/HER2- breast cancer in May 2020 The Council assessed that all three were equally good to treat the disease in terms of their effect and side-effects. Amgros also prepared an expanded basis for comparison, which, among other things, describes the personnel and examination costs linked to using the three medicines.
After this, Amgros held a tendering procedure, in which the companies behind the three equal medicines were invited to submit a tender for their product for Danish patients. The tenders received are confidential, but the companies have all reduced the prices of their medicines.
Up to now, the regions have been spending DKK 190 million a year on the treatment. After the tendering procedure, costs for the same treatment have dropped to about DKK 90 million. The savings assume that the number patients with this type breast cancer remains the same.
“The Danish Medicines Council has assessed that the medicines are clinically equal, so patients can feel safe when we choose the cheapest. This also means we can consider other patients in the healthcare sector,” said Steen Werner Hansen, Chairman of the Danish Medicines Council. He shares the chairmanship with Jørgen Schøler Kristensen.
Amgros CEO, Flemming Sonne, is also pleased with the process:
"This shows that the Medicines Council / Amgros model really works. Ranking the medicines equal in terms of effect means we have created competition for the medicines which would otherwise not exist. This saves the regions money that can be used on treatments for other patients. So we’re constantly finding more cost-effective health solutions,” said Flemming Sonne.
Read the recommendation from the Danish Medicines Council and treatment guidelines concerning CDK4/6-inhibitors for ER+/HER2- locally advanced or metastatic breast cancer here.